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C onsidering surgical repair of coarctation ofthe aorta (CoA) has just celebrated its 70thbirthday (1), evolving through a number of
operative modiﬁcations, it is impressive to consider
that endovascular therapies for CoA, relatively youth-
ful in their existence, have evolved rapidly to become
the treatment of choice in most older children and
adults. In particular, stenting for CoA, yet to reach
25 years since its original description (2), has been
shown to provide excellent short- and long-term out-
comes (3–5). Indeed, in a contemporary multicenter,
nonrandomized evaluation of 350 patients weighing
more than 10 kg undergoing either surgical or trans-
catheter management (stenting or ballooning) of
CoA, stenting was associated with gradient reduction
equivalent to that of surgery; however, with a shorter
hospital stay and fewer complications (6). Stented
patients were more likely to require a planned rein-
tervention, which may reﬂect the lack of an available
balloon-expandable covered stent in the United
States, leading to a relatively conservative dilation
strategy. Either way, this reﬂects a very precocious
development from a relatively youthful procedure.
There are those who may argue that surgery still re-
mains a better option, providing a more comprehen-
sive treatment for the entire spectrum of complex
disease seen within the “syndrome” of CoA (7),
including complex stenoses and aneurysm formation.
However, reports of transverse arch stenting (8) and
aneurysm exclusion (9) have evolved rapidly, indi-
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Suárez de Lezo et al. (10) add to the data base by
conﬁrming the potential for treatment with stenting
of a broad range of complex anatomic substrates seen
in patients with CoA over a 21-year period. Sixty
patients with a mean age of 24 years were retro-
spectively divided into 4 main groups on the basis of
anatomic features: presence of complete interrup-
tion, associated aneurysm formation, complex ste-
nosis, or reintervention for somatic outgrowth of
early stent implantation diameter. A variety of ap-
proaches were used on the basis of the dominant
underlying pathology with one-third of the cohort
having more than 1 complex feature, highlighting the
broad anatomic variability that exists with CoA. Stent
deployment was successful in all cases, with sur-
prisingly no stent migration, an issue seen not infre-
quently in early series describing this approach. The
reduction in pressure gradient in those with domi-
nant stenosis was impressive; however, there was a
death in a 52-year-old male patient who had bare
metal stenting of a diffuse long-segment recoarcta-
tion. One wonders whether a covered stent, had it
been available at the time, might have avoided the
post-procedural demise as recent reports have sug-
gested that older age and longer segment stenosis
may be associated with higher risks of aortic wall
injury (3). One other patient experienced a stroke,
with minor vascular access site injury seen in 4 other
patients and 2 patients requiring blood transfusion
for blood loss, representing a periprocedural compli-
cation rate of 13%, likely reﬂecting the complexity of
pathologies encountered. It is unclear whether the
timing of these complications related to earlier
experience, as has been seen with other series (3).
Over a mean follow-up period of 10 years, the impact
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1381of stenting on blood pressure normalization was
impressive, with almost 80% of the cohort not
requiring medication for blood pressure control. Five
patients required aortic valve surgery, and there was
late mortality in 3 patients thought to be largely
unrelated to stenting, with a 15-year actuarial sur-
vival estimate of 92%, reminding us of the associated
longer term challenges that exist with the diffuse
upper-limb vasculopathy represented by CoA.
So what does this study add to what is already
known about stenting for complex CoA? If each of the
subcohorts were evaluated independently, then
perhaps very little, as stenting for each of these pa-
thologies has been previously described. However,
taken as a whole, this report reminds us of the com-
plex and diffuse nature of the disease that we are
treating and that a full barrage of equipment, occa-
sionally including covered stents, is required if as
interventionalists we are to tackle this syndrome
safely and effectively. It also reminds us of how far
we have come in a short space of time with stenting,
treating the most complex of aortic arch pathologies,supported by rapidly evolving imaging modalities
and a multidisciplinary collaborative approach to
ensure optimal outcomes for our patients. It is un-
clear what the next 25 years of coarctation stenting
will bring us as the procedure matures. One can hope
that a greater understanding of not only the anatomic
consequences of our interventions but also the
physiological impact of rigid stents on ﬂuid me-
chanics within the aorta will come to light. Perhaps
we can hope by the time that stenting for CoA is
celebrating its 50th birthday the suggested upcoming
revolution of bioresorbable scaffolds will be available
to these patients also and continue the goal of re-
establishment of normal vascular function in the
aortas of these unfortunate few. It is likely, therefore,
that the most complex challenges with this disease
are yet to come.
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